Evidence map›Paper›PMID 42151732›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Cognitive dispersion profiles and prediction of cognitive change in early-onset dementias: Results from LEADS.

Dustin B Hammers, Elodie Foster, Ani Eloyan, Maryanne Thangarajah, Alexander Taurone, Alexandra Touroutoglou, Renaud La Joie, Laurel Beckett, Sujuan Gao, Prashanthi Vemuri and 31 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Dustin B HammersDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Elodie FosterDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Ani EloyanDepartment of Biostatistics, Brown University, Providence, Rhode Island, USA.
Maryanne ThangarajahCenter for Biostatistics and Health Data Science, Brown University, Providence, Rhode Island, USA.
Alexander TauroneCenter for Biostatistics and Health Data Science, Brown University, Providence, Rhode Island, USA.
Alexandra TouroutoglouDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Renaud La JoieDepartment of Neurology, University of California - San Francisco, San Francisco, California, USA.
Laurel BeckettDepartment of Public Health Sciences, University of California - Davis, Davis, California, USA.
Sujuan GaoDepartment of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Prashanthi VemuriDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Kelly N NudelmanDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Kala KirbyDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Jeffrey L DageDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Paul AisenAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Alireza AtriBanner Sun Health Research Institute, Sun City, Arizona, USA.
David ClarkDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Gregory S DayDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Ranjan DuaraWien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami, Florida, USA.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Ian GrantDepartment of Psychiatry and Behavioral Sciences, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Lawrence S HonigTaub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
Erik C B JohnsonDepartment of Neurology and Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
David T JonesDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Joseph C MasdeuNantz National Alzheimer Center, Houston Methodist and Weill Cornell Medicine, Houston, Texas, USA.
Mario F MendezDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Leila ParandDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Kyle WomackDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Erik MusiekDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Chiadi U OnyikeDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Meghan RiddleDepartment of Neurology, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Emily RogalskiHealthy Aging & Alzheimer's Research Care Center, Department of Neurology, University of Chicago, Chicago, Illinois, USA.
Stephen SallowayDepartment of Neurology, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Sharon J ShaDepartment of Neurology & Neurological Sciences, Stanford University, Palo Alto, California, USA.
Raymond Scott TurnerDepartment of Neurology, Georgetown University, ., Washington D.C, USA.
Thomas S WingoDepartment of Neurology, UC Davis Alzheimer's Disease Research Center, University of California - Davis, Davis, California, USA.
David A WolkDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Bradford C DickersonDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Gil D RabinoviciDepartment of Neurology, University of California - San Francisco, San Francisco, California, USA.
Maria C CarrilloMedical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
Liana G ApostolovaDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
LEADS ConsortiumDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI BANDEEN-ROCHE, KAREN J. · 1985 to 2019
$37.6M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI VAN DEERLIN, VIVIANNA M · 1991 to 2020
$35.1M
Neuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI VASSAR, ROBERT J · 1996 to 2020
$28.9M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7M
Alzheimer's Association AARG-22-926940Alzheimer's Association K23 AG080071Alzheimer's Association LDRFP-21-818464Alzheimer's Association P30 AG010124Alzheimer's Association P30 AG010133Alzheimer's Association P30 AG013854Alzheimer's Association P30 AG062421Alzheimer's Association P30 AG062422Alzheimer's Association P30AG066506Alzheimer's Association P50 AG005146Alzheimer's Association P50 AG005681Alzheimer's Association P50 AG008702Alzheimer's Association P50 AG023501Alzheimer's Association P50 AG025688Alzheimer's Association P50AG047366Alzheimer's Association R56 AG057195Alzheimer's Association U01 AG016976Alzheimer's Association U01AG6057195Alzheimer's Association U24AG021886NIA NIH HHS K23 AG080071NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG072976NIA NIH HHS P50 AG005146NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG008702NIA NIH HHS P50 AG023501NIA NIH HHS P50 AG025688NIA NIH HHS P50 AG047366NIA NIH HHS R56 AG057195NIA NIH HHS R56AG057195NIA NIH HHS U01 AG016976NIA NIH HHS U01 AG057195NIA NIH HHS U24 AG021886
6 · The paper itself

Abstract

introductionResearch into cognitive dispersion - a cognitive process score measuring the intra-individual variability (IIV) across a single testing session - suggests utility in neurodegenerative populations. Given widespread deficits observed in sporadic early-onset Alzheimer's disease (EOAD), however, it is unclear if examining cognitive dispersion shows benefit in this condition.

methodsA total of 309 participants (188 amyloid-positive EOAD, 43 amyloid-negative early-onset dementia [EOnonAD], 78 cognitively normal [CN]) completed neuropsychological testing twice over 12 months. Dispersion-related differences among groups were assessed, as was cognitive dispersion's capacity to predict domain-specific cognitive trajectories, and its convergence with imaging biomarkers.

resultsEOAD participants displayed higher cognitive dispersion than EOnonAD participants, and associations with EOAD-specific biomarkers. Additionally, cognitive dispersion was associated with 12-month reliable change across several cognitive domains. DISCUSSION: These preliminary results examine cognitive dispersion in sporadic EOAD. When used with baseline cognitive performance, cognitive dispersion measures may enrich future clinical trials in EOAD by enhancing treatment monitoring over time.

Indexed as

Alzheimer DiseaseCognitionDementiaAge of OnsetBiomarkersDisease ProgressionFemaleHumansMaleNeuropsychological TestsBiomarkerscognitioncognitive dispersionearly‐onset Alzheimer's diseaseimaging biomarkerslongitudinal

Identifiers

PMID42151732
PMCPMC13183605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.